Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Highly Profitable Orphans Can Have Exclusivity Reduced Under EC Proposal

Executive Summary

Orphan drugs marketed in the European Union that are found to be making an "unreasonable profit" may face a reduction of market exclusivity time, according to the European Commission's proposal for an orphan products regulation.

You may also be interested in...

EMEA Should Adopt More FDA Methods To Speed Drug Approval - CPMP Chair

The European Medicines Evaluation Agency should consider the adoption of more FDA-style mechanisms to speed approval of important new drugs, Commission for Proprietary Medicinal Products Chairman Jean-Michel Alexandre, PhD, indicated.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts